https://www.optimumcomms.com/wp-content/uploads/2025/12/Oncoinvent_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-01-29 09:02:542026-01-29 09:02:54Four additional sites open for recruitment in Oncoinvent’s Phase 2 trial
https://www.optimumcomms.com/wp-content/uploads/2025/12/Oncoinvent_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-01-29 09:02:542026-01-29 09:02:54Four additional sites open for recruitment in Oncoinvent’s Phase 2 trial
TECregen Appoints Drug Development Veteran Dr. Klaas P. Zuideveld as Chief Executive Officer to Lead Thymus Regeneration Platform into Clinical Development
Appointment builds on CHF 10 million seed financing and Board…

Biocomposites launches SYNICEM™ spacers in Canada
Ready-to-use preformed antibiotic loaded spacers for hip,…

ViCentra Appoints Diabetes Commercialization Leader Reman McDonagh as Vice President, Global Marketing
Marketing executive brings 20+ years of global diabetes experience…

Poolbeg Pharma plc – Peer-Reviewed POLB 001 LPS Challenge Trial Paper Published in Frontiers in Immunology
28 January 2026 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the…

Hansa Biopharma to host Year-end report 2025 conference call
Lund, Sweden, 26 January, 2026. Hansa Biopharma, “Hansa”…

New global consortium aims to transform antibiotic discovery to counter the growing AMR crisis
Philanthropic partners invest US$60 million to support collaborative…

Resolve M Therapeutics exits from stealth
Unique platform designed to engage pro-resolution responses to…

Infinitopes Expands Seed Financing to $35 Million to Accelerate Clinical Development of Precision Cancer Vaccine
Financing co-led by Octopus Ventures and new investor Amplify…

Women in Life Science Denmark (WiLD) expands Nordic footprint with launch of WiLD Finland
WiLD strengthens Nordic collaboration across Denmark, Finland,…

AMSilk’s bioengineered silk protein yarns debut in Balenciaga Spring 2026 Collection
First commercially available products using AMSilk’s biotech…

Novo Nordisk Foundation grants DKK 5.5 billion to elevate innovation in Denmark and Europe
The Novo Nordisk Foundation has allocated up to DKK 5.5 billion…

AMS: Full Year 2025 Trading Update
~ Strong growth in line with expectations, driven by key surgical…

Domain Therapeutics Rebrands as Kainova Therapeutics Advancing Its Clinical Pipeline of GPCR-Modulating Therapies
Kainova Therapeutics rebrand reflects expanding capabilities…

Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines
– 25+ years of biotherapeutics leadership, including serving…

STORM Therapeutics and AlidaBio Announce Strategic Collaboration to Accelerate Development of Cancer Therapies Targeting RNA Modifications
8 January 2026, Cambridge, UK, and San Diego, US: STORM Therapeutics…
We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York